Sinocelltech Group Gets China Nod for Herpes Zoster Vaccine Trial

MT Newswires Live

2024/09/06

China's medical products administrator granted Sinocelltech Group (SHA:688520) subsidiary Sinocell Engineering a clinical trial approval for its SCTV04C recombinant herpes zoster vaccine, according to a Friday filing with the Shanghai Stock Exchange.

Herpes zoster causes painful rashes or blisters on the skin.

The clinical trials will not have any major impact on the company's revenue, the filing said.

Shares slipped 2% during Friday's afternoon trading.

Price (RMB): Â¥32.72, Change: Â¥-0.56, Percent Change: -1.68%

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2465550346"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2465550346\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2465550346?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-06 14:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2465550346","market":"us","top_or_hot":-1,"title":"Sinocelltech Group Gets China Nod for Herpes Zoster Vaccine Trial","media":"MT Newswires Live","content":"<html><body><p> China's medical products administrator granted Sinocelltech Group (SHA:688520) subsidiary Sinocell Engineering a clinical trial approval for its SCTV04C recombinant herpes zoster vaccine, according to a Friday filing with the Shanghai Stock Exchange.</p><p>Herpes zoster causes painful rashes or blisters on the skin.</p><p>The clinical trials will not have any major impact on the company's revenue, the filing said.</p><p>Shares slipped 2% during Friday's afternoon trading.</p><p>Price (RMB): Â¥32.72, Change: Â¥-0.56, Percent Change: -1.68%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinocelltech Group Gets China Nod for Herpes Zoster Vaccine Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinocelltech Group Gets China Nod for Herpes Zoster Vaccine Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-09-06 14:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> China's medical products administrator granted Sinocelltech Group (SHA:688520) subsidiary Sinocell Engineering a clinical trial approval for its SCTV04C recombinant herpes zoster vaccine, according to a Friday filing with the Shanghai Stock Exchange.</p><p>Herpes zoster causes painful rashes or blisters on the skin.</p><p>The clinical trials will not have any major impact on the company's revenue, the filing said.</p><p>Shares slipped 2% during Friday's afternoon trading.</p><p>Price (RMB): Â¥32.72, Change: Â¥-0.56, Percent Change: -1.68%</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"醫藥製造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2465550346","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465550346","pubTimestamp":1725605299,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's medical products administrator granted Sinocelltech Group  subsidiary Sinocell Engineering a clinical trial approval for its SCTV04C recombinant herpes zoster vaccine, according to a Friday filing with the Shanghai Stock Exchange.Herpes zoster causes painful rashes or blisters on the skin.The clinical trials will not have any major impact on the company's revenue, the filing said.Shares slipped 2% during Friday's afternoon trading.Price : 32.72, Change: -0.56, Percent Change: -1.68%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688520":"神州细胞","BK0239":"医药制造"},"translate_title":"Sinocelltech集团带状疱疹疫苗试验获得中国认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688520":0.9},"content_text":"China's medical products administrator granted Sinocelltech Group (SHA:688520) subsidiary Sinocell Engineering a clinical trial approval for its SCTV04C recombinant herpes zoster vaccine, according to a Friday filing with the Shanghai Stock Exchange.Herpes zoster causes painful rashes or blisters on the skin.The clinical trials will not have any major impact on the company's revenue, the filing said.Shares slipped 2% during Friday's afternoon trading.Price (RMB): Â¥32.72, Change: Â¥-0.56, Percent Change: -1.68%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}